The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds. The safety and high tolerability of PDE5 inhibitors make them an attractive tool to investigate further physiological functions of PDE5, for example the modulation of intracellular cyclic GMP (cGMP) pools. As cGMP is a key component of intracellular signaling this may provide novel therapeutic opportunities beyond ED even for indications in which chronic administration is necessary. The approval of sildenafil for the treatment of pulmonary hypertension in 2005 was a notable success in this area of research. A number of other potential new indications are currently in various phases of preclinical research and development. In recent years, extensive but very heterogeneous information has been published in this field. The aim of this review is to summarize existing preclinical and clinical knowledge and critically discuss the evidence to support potential future indications for PDE5 inhibitors.
Introduction
It is well established that nitric oxide (NO) and natriuretic peptides increase intracellular cGMP levels by stimulation of the soluble and membranebound guanylate cyclase, respectively. This cGMP formation is the initial step of a ubiquitous biochemical pathway, regulating the cardiovascular, central and peripheral nervous system. 1 Phosphodiesterases (PDEs) are intracellular enzymes that specifically catalyze the hydrolysis of the second messengers cAMP and cGMP to the inactive metabolites AMP and GMP. Among the 11 families of PDEs a number are able to hydrolyze cGMP, but only PDE5 exclusively catalyses the breakdown of cGMP.
2 By counterbalancing cGMP production by guanylate cyclases, PDE5 is able to decrease cGMP levels very effectively. Thus PDE5 inhibition increases intracellular cGMP levels and initiates a cGMP-driven cascade of reactions. Ultimately, these pathways decrease intracellular calcium levels, thereby promoting relaxation of smooth muscle cells and a variety of other calcium-dependent processes. 3 Since inhibitors of PDE5 raise intracellular cGMP levels, the effects will be much more pronounced under conditions when cGMP formation is already increased. Strong evidence to support this concept is the highly efficacious treatment of erectile dysfunction (ED) with PDE5 inhibitors. 4 Sexual stimulation induces a selective vasorelaxation in penile tissue, which is predominantly mediated by the release of NO in the cavernous nerve endings, the endothelium of penile arteries and the corpora cavernosa. Relaxation is induced by the subsequent formation of cGMP. By preventing degradation of cGMP, PDE5 inhibitors reinforce this physiological mechanism very efficaciously and induce the appropriate vasorelaxation necessary to obtain an erection. It is the regulatory mechanism that forms the basis for the triumphal success of PDE5 inhibitors in the treatment of ED.
Three compounds are available worldwide, three others may enter into the market during the next years ( Table 1) . The wide, safe use of PDE5 inhibitors, together with an increasing understanding of cGMP-regulated mechanisms, have triggered a number of attempts to find new applications for these agents. It has been shown that besides corpus cavernosum, PDE5 is also expressed in smooth muscles of the systemic vasculature, 8 prostate, 9 bladder, 10 cardiac tissues, 11, 12 brain and platelets, 13, 14 which imply additional target tissues for PDE inhibitors. The aim of this paper was to critically review and discuss recent findings in this field, and highlight possible future therapeutic uses of PDE5 inhibitors beyond ED.
PDE5 inhibitors to treat cardiovascular diseases and endothelial dysfunction
PDE5 inhibitors may be optimally suited for the treatment of cardiovascular diseases, due to their mechanism of action. Increases in intracellular cGMP levels cause a relaxation of vascular smooth muscles. This is not only a generalized vasodilation, since its extent depends on the physiological stimulus NO. In regions, where a relatively large NO production signals a high need for local perfusion, the chosen PDE5 inhibitor should be more efficacious than in areas with lower perfusion demand. In contrast to unspecific vasodilators, PDE5 inhibitors trigger a demand-driven increase in flow, which may offer the opportunity for a very specific redistribution of blood flow into areas with the highest perfusion needs. This may prevent luxury perfusion and steal phenomenon and a dramatic decrease in blood pressure.
Other effects beyond vascular dilatation have been described for PDE5 inhibitors, which may also have a positive impact on cardiovascular diseases. There are numerous reports that describe protective effects in ischemia/reperfusion in the heart. 15 Other authors have reported antihypertrophic, 16 antiproliferative, 17 and antifibrotic 18 efficacy.
Pulmonary hypertension
The treatment of pulmonary arterial hypertension is the most established cardiovascular use of PDE5
inhibitors. There is a large body of preclinical and clinical evidence showing that PDE5 inhibitors reduce vascular resistance in the pulmonary circulation and pressure in the pulmonary arteries. The rationale is based on the hypothesis that oxygenation of the alveoli stimulates release of NO, which causes a local relaxation of pulmonary resistance vessels. Inhibition of cGMP cleavage results in amplification of this regulatory pathway, causing increased vasodilation without inducing a ventilation-perfusion mismatch.
In animal models, such as the monocrotalineinduced pulmonary hypertension (PAH) in rats, it has been demonstrated that the PDE5 inhibitor sildenafil reduces pulmonary arterial pressure and right heart hypertrophy. 19 Moreover, it has been shown that inhibition of cGMP cleavage by sildenafil reduces the hypoxia induced rise in pulmonary pressure and partially reverses pulmonary artery muscularization. 20 In clinical studies sildenafil also has been shown to be a safe and effective drug for patients with PAH. A small crossover study showed that sildenafil improved exercise time and cardiac output significantly, whereas pulmonary arterial pressure was only slightly decreased. 21 In the SUPER-1 (Sildenafil Use in Pulmonary Hypertension) study (a large, randomized, controlled, multinational trial) sildenafil significantly improved exercise capacity, functional class and hemodynamic parameters and was well-tolerated. 22 On the basis of these data, sildenafil was approved in 2005 by the United States Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products for the treatment of patients with PAH.
Heart failure Congestive heart failure (CHF) is a chronic debilitating disease, which leads to infirmity and death within few years. Coronary artery disease, past myocardial infarctions and hypertension are the major causes of heart failure.
There are numerous potential mechanisms by which PDE5 inhibitors could exert positive effects on the course and symptoms of this disease. The most prominent mechanism is a cGMP-mediated relaxation of smooth muscle cells, which elicits a direct vasodilation. Since this is observed primarily in the pulmonary vasculature, it may particularly unload the right ventricle. In patients suffering from CHF, sildenafil decreased pulmonary resistance and improved peak oxygen uptake during exercise, whereas it did not influence these parameters in healthy volunteers. 23 The positive effect of direct vascular dilation may be important in large blood vessels, since an improved compliance of the large arteries reduces peak ventricular pressure and improves peripheral perfusion during the diastole 24 In patients with controlled LV failure and ejection fractions lower than 35%; a single dose of 50 mg sildenafil improved cardiac performance by decreasing peripheral resistance, aortic and large artery stiffness and wave reflection from peripheral sites.
Another potential benefit of PDE5 inhibitors may be an improvement of endothelial function. 25 A placebo-controlled study showed that acute PDE5 inhibition with sildenafil-increased endotheliumdependent, flow-mediated vasodilation in patients with chronic heart failure. 26 These findings were confirmed by Hryniewicz et al., 27 who compared sildenafil with the angiotensin-converting enzyme inhibitor ramipril, showing that both compounds improved flow-mediated dilation to a similar extent in patients with heart failure.
It is not clear to what extent the vascular effects of PDE5 inhibitors affect coronary and left ventricular hemodynamics. In an experimental model of pacing-induced heart failure, Chen et al. 28 observed that sildenafil only caused a slight decrease of aortic pressure, without any change in heart rate, left ventricular systolic pressure and contractility, coronary flow or myocardial oxygen consumption, either at rest or during exercise. In contrast to findings in normal animals, sildenafil did not augment endothelium-dependent coronary vasodilatation in response to acetylcholine in animals with CHF.
In 2005, Takimoto et al. 16 presented an intriguing study showing that the sildenafil completely suppresses cardiac hypertrophy in mice exposed to chronic pressure overload by an aortic banding protocol. They also demonstrated that the drug even reversed a pre-established hypertrophy. A suggested mechanism of action was deactivation of multiple hypertrophy signaling pathways such as calcineurin/ NFAT, phosphoinositide-3 kinase/Akt and ERK1/2. However, such a dramatic effect is difficult to understand and requires further investigation.
In summary, there is substantial evidence that PDE5 inhibitors may have positive effects in heart failure and cardiac hypertrophy. However, the potential mechanisms of action are not fully understood and the clinical benefit remains to be demonstrated.
Raynaud's disease
Raynaud's disease is characterized by temperaturesensitive, digital vasospasms leading to pale, cyanotic skin mostly limited to the digits. Unlike the uncomplicated, primary idiopathic Raynaud's phenomenon, the secondary form is linked to connective tissue diseases. This form presents more severely, with potentially disabling ulceration or tissue necrosis. Non-pharmacological therapy includes avoidance of cold temperatures, emotional stress and smoking. Pharmacological treatments, however, are often disappointing and inefficient.
Although there are numerous hypotheses, the mechanism of local vasoconstriction is not well understood. 29 Nevertheless, there is increasing evidence that the NO/cGMP system plays a major role. In scleroderma patients intra-arterial infusions of L-arginine (the substrate for NO) and sodium nitroprusside (a direct donor of NO) significantly decreased the occurrence of laboratory-induced Raynaud's phenomenon. 30 Rosenkranz et al. 31 published a case report of a 65-year-old woman with severe Raynaud phenomenon related to systemic scleroderma. Treatment with sildenafil improved severity and frequency of acrocyanosis, and laserDoppler flowmetry demonstrated improved perfusion of the fingertips.
In an open-label pilot study, Caglayan et al. 
PDE5 inhibitors to treat central nervous system disorders
PDEs are abundantly expressed in central nervous system (CNS) tissue 34 and there are an increasing number of reports on the effects of PDE5 inhibitors on the CNS. 35 Studies have shown that both PDE5 mRNA and PDE5 enzyme was detected in many parts of the brain (for example, cortex, cerebellum and hippocampus) [36] [37] [38] and also in blood vessels within the brain (for example, cerebral, basilar and mesenteric artery). 39 This suggests that the NO/ cGMP pathway may be involved in a multitude of cerebral functions and may play a central role in brain metabolism. A number of in vitro and in vivo studies have investigated the effects of selective PDE5 inhibitors on cognitive functions and their neuroprotective effects in stroke models. The presence of PDE5 in the CNS might explain why PDE5 inhibitor treatment may result in some degree of back pain and myalgia as side effects of therapy. Data obtained from a rat model using sildenafil PDE5 inhibitors beyond erectile dysfunction P Sandner et al suggest a modulation of nociception by centrally mediated effects. 40 However, only limited information is available on the extent to which these drugs penetrate the blood-brain barrier. 41 Effects of PDE5 inhibitors on learning and memory In vitro experiments have demonstrated that sildenafil and vardenafil both increase NO-mediated cGMP accumulation in slices of rat hippocampus. 36 Increased cortical levels of cGMP have also been demonstrated in vivo in rats treated with sildenafil. 42 The functional role of cGMP was first demonstrated in behavioral studies in rats. Injections of 8-bromo-cGMP into hippocampus improved memory performance in tasks of object recognition and passive avoidance retention. 43 Subsequent animal studies with sildenafil have demonstrated the longterm retention of an inhibitory avoidance response in mice. 44 Moreover, oral administration of the PDE5 inhibitors sildenafil and vardenafil (1-10 mg/kg) immediately after training effectively improved the memory performance of rats in object recognition tasks. 36, 45 Thus, it may be argued that inhibition of PDE5 in the dorsal hippocampus improves object recognition memory, which may result from increased levels of cGMP. This hypothesis is supported by the finding that learning impairment in rats can be induced by administration of the NOsynthase inhibitor L-NAME which, in turn, can be attenuated by intraperitoneal administration of sildenafil. 46, 47 The effects of PDE5 inhibitors on memory processes in humans have only been studied sporadically. So far, no clear effects on behavioral measures of attention and verbal recognition memory have been reported. 48 However, one study found that attention-and event-related brain potential measures were improved by sildenafil. In another study, the simple choice reaction time was reported to be faster in sildenafil-treated subjects. 49 In conclusion, there is a clear body of evidence that these drugs have the potential to improve memory performance in animals, particularly in the early consolidation process of long-term memory. This memory improvement might be mediated by elevations in central cGMP levels. Studies in humans suggest that information processing may be improved by sildenafil treatment. However, further studies designed to test memory-enhancing effects of PDE5 inhibitors are needed to demonstrate a proof of principle for this class of drugs as a possible tool for improving memory.
Stroke A number of publications from one particular research group deliver growing experimental evidence that the NO/cGMP pathway is implicated in repair mechanisms in rodent models of stroke.
Oral treatment of rats with sildenafil (2 or 5 mg/ kg) 24 h after embolic stroke improved recovery of neurological outcome. Although there was no difference in infarct volume between the treated and untreated groups, sildenafil stimulated cell proliferation in the subventricular zone and striatum, as indicated by an enhanced number of immature neurones. 42, 50, 51 The potential of PDE5 inhibitors to augment neurogenesis was demonstrated in a model using aged rats. These animals exhibit a greater impairment of neurological recovery after focal ischemia, compared with young rats. However, treatment with sildenafil (10 mg/kg), even 7 days after ischemia, significantly improved functional recovery, vascular density, endothelial cell proliferation and synaptogenesis, compared with untreated rats. These effects were also observed in younger rats at lower doses (2 mg/kg). 52 All of these effects may contribute to the significantly improved functional recovery observed in sildenafil-treated, compared with saline-treated rats. Studies carried out by the same research group showed that increased cGMP levels induced neurogenesis in adult progenitor cells derived from the subventricular zone through activation of the phosphoinositol-3-kinase/Akt glycogen synthase kinase-3 pathway. 53 Few studies have been published on the effects of sildenafil on cerebral blood flow (CBF) and oxygenation, and results are controversial. [54] [55] [56] [57] Studies in healthy subjects found no effect on CBF after treatment with oral sildenafil. 55 However, results in stroke models in rats are extremely encouraging. Nevertheless, one has to keep in mind that due to the lack of clinical data the use of PDE5 inhibitors is not indicated in stroke patients 6 months after acute stroke. Therefore, a proof of concept study in humans with acute stroke have to be conducted very carefully, but would be desirable to assess the potential of these drugs for this indication.
PDE5 inhibitors to treat urological disease
Female sexual dysfunction The physiology of female sexual response is poorly understood. Only a small number of experimental studies have investigated the possible role of PDE5 in the physiology of female genital organs. The occurrence and hydrolytic activity of PDE5 in human clitoral corpus cavernosum and human vagina has been shown. [58] [59] [60] Organ bath experiments have demonstrated the ability of PDE5 inhibitors to relax vaginal and clitoral muscles. 61, 62 Thus, it is logical to expect that PDE5 inhibitors may improve vaginal and clitoral blood flow and facilitate arousal and orgasm in women. To date, only PDE5 inhibitors beyond erectile dysfunction P Sandner et al sildenafil has been investigated clinically for effects on female sexual function. However, the results of these clinical trials were not very encouraging. Sildenafil showed only moderate effects to most women with female sexual dysfunction (FSD). [63] [64] [65] [66] Studies showed that PDE5 inhibition may benefit individuals with female sexual arousal disorder (FSAD), but not with hypoactive sexual desire disorder (HSDD). This finding might be especially important for women with diabetes as FSAD is the most commonly reported sexual problem in this group of patients. 67 Indeed, it has recently been shown that sildenafil improved sexual function in premenopausal women with diabetes. 68 Thus it appears that certain patient groups may benefit from treatment with PDE5 inhibitors, but further studies are required to confirm this.
When planning future studies, new findings concerning female sexuality should be taken into consideration. The linear model of sexual response, which is true for men, disregards the relative independence between subjective and objective aspects of women's sexual response. 69 This can explain the lack of correlation between the improvement of objective arousal (for example, increase of clitoral blood flow) and the subjective sexual feelings. Moreover, the frequency of sexual fantasies or sexual thought has little correlation with sexual satisfaction in women. 70, 71 Thus daily diary measures, event logs or number of successful or satisfactory sexual events might not be the most sensitive and reliable measures of outcome in FSD clinical trials. 72 Therefore, in light of these findings, any clinical studies to evaluate the benefits of PDE5 treatment for women with FSD may require a modified design.
Benign prostate syndrome and lower urinary tract symptoms (BPS/LUTS)
Benign prostate syndrome (BPS) comprises lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH), which can cause bladder outlet obstruction (BOO). LUTS may also be present in patients without benign prostate enlargement (BPE). LUTS comprises obstructive symptoms and irritative symptoms: obstructive symptoms are induced by compression of the urethra caused by BPE; irritative symptoms occur during the filling phase of the bladder and are characterized by non-voiding contractions of the bladder detrusor muscle. [73] [74] [75] LUTS considerably decreases the quality of life of affected patients and is a major healthcare problem in developed countries. The main treatment options -besides prostatic surgery -are a-blockers and 5-a reductase inhibitors. 76, 77 PDE activity in human prostate tissues was first reported in 1970. 78 Later studies demonstrated that various PDE isoenzymes, including PDE5, are expressed in the prostate. 9, 79 Various PDE inhibitors, including zaprinast (used for PDE5 inhibition), are able to relax human prostate tissue in vitro. 9, 80 There is also recent evidence that the PDE5 inhibitors vardenafil, sildenafil and tadalafil are able to relax prostate, bladder and urethral tissues in vitro. 17 Moreover, preclinical research has demonstrated a reduction of non-voiding contractions in vivo in rats treated with vardenafil or sildenafil. 17, 81 Even more striking are the recent observations from clinical studies, where a reduction of LUTS was reported in patients with BPH treated with sildenafil and tadalafil. [82] [83] [84] The International Prostate Symptom Score (IPSS), which includes obstructive and irritative scoring, was significantly reduced in patients with BPS treated with 100 mg sildenafil or 20 mg tadalafil, once daily, for 12 weeks. In both studies, there were no changes in urodynamic parameters and positive effects were related to improvement of symptoms. There is therefore evidence that PDE5 inhibitors may be an additional treatment option for patients suffering from LUTS.
Overactive bladder and incontinence
Overactive bladder (OAB) is a term, defined by the International Continence Society, and is usually described as urgency with or without incontinence, frequency and nocturia. 85 Urgency urinary incontinence (UUI) is a sudden and compelling desire to pass urine, which can be accompanied by the involuntary leakage of urine. In addition, OAB patients display higher voiding frequency, with 48 episodes of voiding during daytime and nocturia, with more then 1 voiding during sleeping time. Urge urinary incontinence (UUI) is the most bothersome symptom of OAB and is associated with a significantly reduced quality of life of the patients. 86 The pathophysiology of this disease is not fully understood and seemed to be multifactorial. The voiding process is normally tightly regulated by neural circuits within the brain and the spinal cord, which co-ordinate smooth muscle activity in bladder and urethra. Direct contraction and relaxation of the bladder smooth muscle plays a critical role in this disease. 87 In addition to local application of botulinum toxin or resiniferatoxin, 88, 89 the main treatment option is based on muscarinic receptor antagonists (antimuscarinics). These prevent acetylcholine-induced contraction of the detrusor muscle by blocking post-synaptic M3 receptors during the filling phase. 90, 91 Evidence that PDE inhibitors may be used for the treatment of OAB and UUI is rare and is only indirect. It has been shown that different PDE isogenes, including PDE5, are expressed in the detrusor muscle. 10 Further, PDE inhibitors, including PDE5, reduced the tonus of bladder muscle in vitro. [92] [93] [94] [95] As these effects are relatively weak, there is increasing evidence that the effects of PDE5 PDE5 inhibitors beyond erectile dysfunction P Sandner et al inhibitors are at least in part related to their influence on the urothelium. It was shown in guinea pigs that urothelial, suburothelial and intramural neurons contain considerable amounts of endothelial NO synthase (eNOS) and NO-inducible cGMP, which may be important for bladder sensations and the micturition threshold. 96, 97 There is preliminary evidence regarding the effects of the PDE-1 inhibitor, vinopectine, in patients with OAB. 98 However, as yet, clinical data to support the use of PDE5 inhibitors for the treatment of OAB are limited. The symptoms of LUTS (urgency, frequency, nocturia) in patients with BPH are similar to those of UUI in patients with OAB. 75 Both LUTS and UUI symptoms originate within the bladder and are characterized by detrusor overactivity. 75 This may explain the finding that the M3 antagonist, tolterodine, which is normally used in patients with OAB, significantly improved the symptoms of LUTS when used in patients with BPH. 99, 100 Thus, it might be assumed that if PDE5 inhibition reduces symptoms of LUTS, it may also reduce UUI symptoms in patients with OAB. 82, 84, 101 Both preclinical models and clinical studies are required to investigate the efficacy of marketed PDE5 inhibitors in the treatment of OAB.
Premature ejaculation
Premature or rapid ejaculation (PE/RE) is a common male sexual disorder with prevalence rates of 5-30%. [102] [103] [104] However, the pathophysiology and underlying molecular mechanism are only poorly understood. No approved pharmacotherapy is currently available, but tricyclic antidepressants, serotonin reuptake inhibitors and topical applications of local anaesthetics are used in the treatment of this condition. 105 Psychological counseling and behavioral therapy, either alone or in combination with drug treatment, have also shown success. 106 However, current treatment options are limited both in their efficacy and also, partly, by their side effects. Consequently, substantial efforts are underway both to increase understanding of the pathophysiology of PE, and to search for more effective therapies. Research has shown that relaxation of smooth muscles within the vas deferens and seminal vesicles may attenuate ejaculation, a finding which may be useful in developing therapies for PE. The role of the NO/cGMP pathway in PE has been investigated and it was found that NO-donors [107] [108] [109] [110] are able to relax the vas deferens and seminal vesicles. 111 Moreover, it was also reported that eNOS knockout mice (lacking the gene for endothelial NO synthase) have higher rates of ejaculation, with less stimulation required to elicit ejaculation, compared to wild type mice. 112 Despite the involvement of the NO/cGMP system in PE, preclinical in vivo results with PDE inhibitors are still missing. However, the PDE5 inhibitors sildenafil, vardenafil and tadalafil have been used to treat PE/RE patients in several clinical studies. 113, 114 In these studies an increased intravaginal ejaculatory latency time (IELT) was found after treatment with sildenafil, 115 vardenafil 116 and tadalafil. 117 However, these studies were often performed in an open label manner, with poorly defined inclusion criteria and without consistent objective physiological end points. Therefore, despite these very promising clinical results only one clinical trial conducted with sildenafil fulfilled the evidence-based medicine criteria. 113 In this placebo-controlled, double-blind study within almost 160 patients, no significant increase in IELT was observed. However, patients treated with sildenafil reported significantly increased ejaculatory control, increased ejaculatory confidence and had a decreased post-ejaculatory erectile refractory time. 118 Thus, further preclinical research on the role of PDE inhibitors in PE is required, together with clinical trials to evaluate the potential benefits of PDE5 inhibitor treatment for patients with PE.
Peyronie's disease Peyronie's disease (PD) is a disorder characterized by fibrotic plaques of the tunica albuginea of the penis. The prevalence rate of PD is estimated to be between 0.4% and 9%, depending on the exact criteria used to define the condition. 119, 120 The cause of fibrotic plaques in patients with PD is unknown, but it is hypothesized that trauma with excessive wound healing, infections and autoimmune disease may cause this local fibrosis within the penis. The molecular mechanisms underlying this condition are poorly understood. Pharmacotherapy is still in an experimental stage, and therefore surgery is currently the predominant treatment option. 119 As the proliferation and accumulation of fibroblasts in the penis promote PD, one possible therapeutic approach is the prevention of fibroblast proliferation. It has been demonstrated that the NOS/NO/cGMP system plays an important role in the progression of plaque development, since inhibition of inducible NO synthase (iNOS) results in exacerbated fibrosis. 121 In primary cultures of human PD-derived fibroblasts, sildenafil and the nonspecific PDE inhibitor, theophyllin, reduced collagen I synthesis and myofibroblast differentiation and increased apoptosis in vitro. 122 Very recently, an in vivo rat model of PD was used to demonstrate that vardenafil significantly decreased collagen I and III deposition and reduced the numbers of myofibroblasts in PD plaques. 123 There is currently no clinical data to support the use of PDE5 inhibitors for the treatment of PD. Therefore, a future goal should be to confirm the existing in vitro and in vivo preclinical evidence in clinical trials to evaluate the potential of PDE5 inhibitors for the treatment of PD.
PDE5 inhibitors beyond erectile dysfunction P Sandner et al Priapism Priapism is a rare disease within the general population. However, in certain patient groups (for example, patients with sickle cell disease) the incidence of priapism may be as high as 40%. The pathophysiology of priapism is still elusive, but it is thought that the persistent erections observed in patients with this condition may be due to dysfunctional penile blood flow. 124, 125 Data from several small clinical trials suggest that PDE5 inhibitors may be used successfully for the treatment of priapism. 126 It is hypothesized that long-term treatment with sildenafil may prevent downregulation of PDE5 protein, and therefore prevent the chronic cGMP accumulation and excessive penile blood flow seen in patients with priapism. 127 This hypothesis must now be confirmed in clinical trials with larger numbers of patients.
Conclusions
PDE5 inhibitors are the gold standard for treatment of ED. The efficacy, wide availability, safety and high tolerability of this class of drugs have made them the focus of extensive research by both, basic researchers and clinicians in recent years. Moreover, based on a variety of clinical studies with daily dosing for the treatment of ED, and the use of sildenafil for treatment of PAH chronic dosing of PDE5 inhibitors has not raised serious safety problems up to now. From the studies in patients with ED-and LUTS-treated 12 weeks with Viagra once daily, there were only little side effects, mainly dyspepsia and head ache, reported. 82 However, there is still lack of sufficient clinical data about long-term chronic treatment with daily-dosed PDE5 inhibitors to assess completely the risk-benefit potential for new indications. This finding is important, as many of the proposed new indications for PDE5 inhibitors would require chronic daily dosing. Although many of the new research avenues are still in their early stages, there is a strong possibility that some will move from bench to bedside ( Table 2) .
Many of the new indications for PDE5 inhibitors are characterized by regional deficiencies in blood supply, which can be modulated via the NO-cGMP pathway. The use of PDE5 inhibitors may be beneficial due to their capacity to reverse endothelial dysfunction and to selectively improve NOmodulated regional blood flow in areas of greatest need (for example, in Raynaud's disease). Moreover NO/cGMP might also have antifibrotic effect, which is necessary for the treatment of fibrotic disorders (for example, PD). The successful development of sildenafil for the treatment of PAH demonstrates that it is possible to take advantage of both hemodynamic and anti-remodelling mechanisms beyond ED.
The rationale for the use of PDE5 inhibitors for the treatment of heart failure is similar to that for PAH. Inhibition of PDE5 induces a reduction in vascular resistance in the pulmonary circulation, which unloads the right ventricle. However, there are a number of other potential mechanisms by which PDE5 inhibitors may have a positive influence on heart failure, and the impact of these effects is, as yet, unclear. Therefore, despite a variety of encouraging 22 Heart failure Aortic banding in mice, 16 only minor effects in pacing induced heat failure in dogs 28 Improvement in flow-mediated vasodilatation in CHF patients 26, 27 Raynaud's disease None Significant reduction in frequency and duration of Raynaud attacks 33 Cognitive dysfunction PDE5 expression profiling, [36] [37] [38] [39] in vitro studies, 36, 42 behavioral models with rodents [43] [44] [45] [46] [47] None Stroke Various stroke models in rats 42, [50] [51] [52] [53] None Female sexual dysfunction PDE5 expression and activity in vitro [58] [59] [60] ; isolated organ bath 61, 62 Moderate effects in pre-and post-menopausal women, [63] [64] [65] [66] 126, 127 Abbreviations: BPS, benign prostate syndrome; CHF, congestive heart failure; LUTS, lower urinary tract symptoms; PAH, pulmonary hypertension; PDE5, phosphodiesterase type-5.
PDE5 inhibitors beyond erectile dysfunction P Sandner et al data from animal models, the road to clinical practice may be long. Evidence to support the potential use of PDE5 inhibitors for the treatment of CNS disorders is mainly based on the presence of PDE5 in morphologically distinguishable structures in the CNS, together with a number of preclinical in vitro and in vivo studies demonstrating the functional role of PDE5. The encouraging effects of sildenafil in several models of stroke, and the positive effects on enhancement of recognition raise some optimism for future treatment options, although further evaluation is required.
Clinical studies with sildenafil demonstrated that a positive effect in the treatment of FSD could be achieved in women with arousal problems, but not in those with desire problems. New findings show that women who experience sexual problems as a result of conditions such as diabetes may benefit from treatment with PDE5 inhibitors. However, further clinical studies using a modified design, which take into consideration new findings on female sexuality may be necessary.
The effectiveness of PDE5 inhibitors in treatment of PE is still under debate. Most of the clinical studies carried out have the potential for bias and have provided no conclusive evidence. Hence, further preclinical and clinical studies are needed to evaluate the use of PDE5 inhibitors for the treatment of this condition.
There are encouraging data from preclinical research, which show that PDE5 inhibitors are able to relax prostate, bladder and urethral tissues in vitro and reduce irritative symptoms in vivo. These data are further supported by strong clinical evidence showing that sildenafil, vardenafil and tadalafil treatment caused a significant improvement of the symptom score in LUTS patients. This clearly raises the expectation that PDE5 inhibitors may become a new treatment option for LUTS in the future. It is known that LUTS in BPS patients is similar to UUI in OAB patients. Thus, the efficacy of PDE inhibitors for the treatment of patients with OAB symptoms may also be assumed.
The PDE5 inhibitors are an exciting class of drugs with a unique mechanism of action, combined with a favorable safety profile. Recent, intense preclinical and clinical research with PDE5 inhibitors has revealed new mechanisms and a number of potential new indications for these drugs. It is envisaged that the PDE5 inhibitors may become valuable future treatment options for a variety of diseases beyond ED.
